Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
By D. Planchard, S. Popat, K. Kerr, S. Novello, E. Smit, C. Faivre-Finn, T. Mok, M. Reck, P. V. Van Schil, M. Hellmann and 1 more. Annals of Oncology, 2018
2,397 citations recorded by the source corpus.
Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France; Royal Marsden Hospital, London; Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK; Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy; Thoracic Oncology Service, Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; LungenClinic Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany; Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium; Weill Cornell Medical College, New York, USA; Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Subfields: Cancer Research, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/df986e3aedeaac78790895a7c9fb6c517c464d5b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer (2019, background): “In view of these results, osimertinib has been propelled into first-line therapy for patients with advanced or metastatic NSCLC with activating EGFR mutations, regardless of their T790M status.(13) Despite these results, the possibility of sequencing treatment with first-/secondgeneration EGFR-TKIs ”
- Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018, background): “Number of patients with CNS progression* 10 (19) 27 (43) 7 (3) 15 (7) Progression in CNS only 3 (6) 10 (16) 4 (2) 12 (6) New lesions only 3 (6) 9 (14) 4 (2) 12 (6) Non-target lesions only 0 0 0 0 New and non-target lesions 0 1 (2) 0 0 Progression in CNS and non-CNS 7 (13) 17 (27) 3 (1) 3 (1) New les”
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022, positive): “65 In treatment-naive NSCLC, ctDNA can be considered complementary or alternative to tissue NGS for biomarker evaluation.”
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, neutral): “In contrast to stage IV [14], the consequences of the upfront diagnosis for selecting the most effective therapy of stages I–III NSCLC are assumed to be less relevant.”
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer (2018, positive): “Genotyping, whether for the existence of EGFR T790M mutations or other oncogenic alterations, is a crucial step in guiding future treatment, according to the current NSCLC guidelines [47, 48].”
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). (2017, positive): “On the basis of clinically relevant and statistically significant improvements in OS from CheckMate 017 and CheckMate 057,(5,6) nivolumab was approved by multiple regulatory authorities(12,13) and incorporated into clinical practice guidelines for NSCLC treatment.(16,17) Additional follow-up from th”